From Contract to Collaboration: Navigating Vendor Management in Clinical Trials

We’re pleased to invite you to a short seminar

Date: Wednesday, July 23rd, 2025
Time: 08:30–13:00
Location: Alon Hall, IMP Facility (SLE), Hate’ena 1 st., Modiin Region Industrial Park
Waze: סלא טבע שוהם

Join us for a focused and insightful seminar exploring the evolving landscape of vendor management in clinical trials — from oversight to strategic collaboration, from building networks to maximizing local advantages.

Agenda

08:30–09:00	Registration & Coffee
09:00–09:15	Opening Remarks Limor Teomim, CEO, IMP
09:15–09:45	Introduction to the Service Providers Community Roy Zaibel, Co-CEO, ADRES
09:45–10:15	Sponsor Oversight According to ICH E6 Rivka Zaibel, President and Founder, ADRES
10:15–10:45	From Selection to Partnership: Strategic Collaboration in Clinical Supply Management Limor Teomim, CEO, IMP
10:45–11:15	Coffee Break
11:15–11:45	Laying the Foundation: How a Growing Sponsor Built Its Vendor Network Donna Ehrenberg, VP Clinical Operations, Elgan Pharma
11:45–12:15	Vendor Risk and Oversight: Balancing Speed with Compliance Sofi Glam, VP Business Development & Customer Success, IMP
12:15–12:45	Panel: Vendor Decisions: Choosing, Managing, Collaborating Moderator: Limor Teomim, CEO, IMP – Sofi Glam, VP Business Development & Customer Success, IMP – Donna Ehrenberg, VP Clinical Operations, Elgan Pharma – Noga Brunicki, Owner, NovaTrials – Clinical Research Organization
12:45–13:00	Closing Remarks

Intended audience:
Companies, startups, and professionals involved in the planning, execution, or support of clinical trials — including (bio)pharmaceutical and medical device innovators at or approaching a clinical stage, as well as CROs, service providers, and clinical operations teams seeking to optimize vendor collaboration.

Free of charge for IMP customers
For participants that are not yet clients of IMP
the price per participant is 480 NIS + VAT

Registration is mandatory and will be pre-approved

Up to 2 participants per company. Additional participants require payment in full

Enabling the Safe Importation of Advanced Therapies and CAR-T Treatments in Israel

What Are Advanced Therapies and CAR-T Treatments? Advanced therapies — including cell and gene therapies (CGTs) such as Chimeric Antigen Receptor T-cell (CAR-T) therapies — represent a major leap forward in modern medicine. These innovative, patient-specific therapies are designed to use living cells to repair or replace damaged tissue, treat cancers, and in some cases, […]

Risk Management and Vendor Partnerships in Clinical Trials Logistics: Building Resilient Supply Chains

In clinical trials, logistics are the invisible backbone. From investigational medicinal products (IMPs) and ancillary supplies to temperature-controlled storage and timely distribution, each element must function with precision. But what happens when a link in the chain breaks? Supply chain disruptions—caused by global events, vendor failures, regulatory hurdles, or logistical delays—can jeopardize timelines, budgets, and, […]

Navigating 29C Importation in Israel

What is 29C Importation? Regulation 29C governs the importation of non-registered medicinal products into Israel under specific conditions. This regulation allows hospitals, healthcare providers, and sponsors to access treatments that are not locally registered but are essential for patient care. These imports often support clinical trials, compassionate use programs, or off-label treatments when no registered […]

From Contract to Collaboration: Navigating Vendor Management in Clinical Trials